Merck and Gilead discontinue Phase III KEYNOTE-D46/EVOKE-03 study

CellmRNA 3′ UTRs chaperone intrinsically disordered regions to control protein activity

Clinical OMICsBeyond the Genome: Five Emerging Leaders in Epigenetics Diagnostics

BioPharma DiveStealthy startup Treeline plans a reverse merger

10x Genomics Blog10x Genomics Acquires Proteintech Genomics to Expand Single-Cell Proteomics Portfolio - citybiz

Endpoints NewsHow K Health moved AI chatbots into hospitals

10x Genomics News10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group - BioSpace

Endpoints NewsLilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drug

Endpoints NewsTrodelvy misses in lung cancer, but Gilead and Merck have an HIV success

FierceBiotechADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal program

FierceBiotechLilly moves deeper into Alzheimer’s research with AlzeCure licensing deal

FierceBiotechCancer biotech Parabilis ups IPO plans to potentially record-setting $637M

Endpoints NewsEndpoints Women in Biopharma: Nominate for 2026